Kriya is a fully integrated company pioneering novel technologies and therapeutics in gene therapy. We aim to revolutionize how gene therapies are designed, developed, and manufactured, improving speed to market and delivering significant reductions in cost per dose.
Kriya is organized into four principal business units: Kriya Technologies™, Kriya Therapeutics™, Kriya R&D™, and Kriya Manufacturing™. We are advancing a deep and diversified pipeline of innovative gene therapies in multiple therapeutic area divisions, with current pipeline programs in ophthalmology, oncology, rare disease, and chronic disease.
We believe that rationally engineered and manufactured gene therapies can transform the treatment of a broad universe of diseases – and we are prepared to lead this revolution in medicine.
SIRVE™ is our proprietary computationally-enabled platform for rational vector design, sequence modification, and data analysis.